symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
IMNM,8.75,1.720627,45254,373879625,0,2.2-9.5299,-0.17,"Immunome, Inc.",USD,0001472012,US45257U1088,45257U108,NASDAQ Capital Market,NASDAQ,Biotechnology,https://immunome.com,"Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.",Dr. Clay B. Siegall Ph.D.,Healthcare,US,37,610 321 3700,665 Stockton Drive,Exton,PA,19341,,0,https://financialmodelingprep.com/image-stock/IMNM.png,2020-10-02,False,False,True,False,False
